| Ticker Symbol | Entity Name | As Of Date | Company Name | Followers | Employees on Linkedin | Link | Industry | Date Added | Date Updated | Description | Website | Specialities | Logo | HQ.Street | HQ.City | HQ.State | HQ.Country | HQ.Postal | Headcount change in past 24 months | Company Name | Sector | Industry |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| private:pangenxinc.-2 | 1458440 | May 30th, 2019 12:00AM | PanGenX, Inc. | 226 | 0.00 | Open | Biotechnology | May 30th, 2019 07:53PM | May 30th, 2019 07:53PM | PanGenX was founded in 2010 with the belief that current treatment outcomes can be improved through effective use of clinical genetic data. We have created a deep collaboration between geneticists and computer scientists. This unique combination has led to the creation of scientifically based, technology driven, decision-making applications to improve the lives of millions of patients suffering worldwide. Our passion, combined with tenacious efforts to challenge status quo drives our team to bring personalized medicine to the forefront of healthcare. Our mission is to advance clinical practice and treatment approaches by integrating genetic variations related to drug response with patient outcomes. We optimize therapeutic care and decision-making by providing pharmaceutical companies, healthcare providers, and payers with tools to conduct analyses and make more informed decisions through the intelligent use of pharmacogenomics, population genetics, and clinical outcomes data. Ultimately, by informed selection of medicines, patients will endure less side effects and achieve treatment benefits for debilitating, progressive diseases. | Open | Open | Craftsland Road | Brookline | MA | US | 02467 | PanGenX, Inc. | ||||
| private:pangenxinc.-2 | 1458440 | Nov 7th, 2017 12:00AM | PanGenX, Inc. | 222 | 0.00 | Open | Biotechnology | Nov 7th, 2017 04:55PM | Nov 7th, 2017 04:55PM | PanGenX was founded in 2010 with the belief that current treatment outcomes can be improved through effective use of clinical genetic data. We have created a deep collaboration between geneticists and computer scientists. This unique combination has led to the creation of scientifically based, technology driven, decision-making applications to improve the lives of millions of patients suffering worldwide. Our passion, combined with tenacious efforts to challenge status quo drives our team to bring personalized medicine to the forefront of healthcare. Our mission is to advance clinical practice and treatment approaches by integrating genetic variations related to drug response with patient outcomes. We optimize therapeutic care and decision-making by providing pharmaceutical companies, healthcare providers, and payers with tools to conduct analyses and make more informed decisions through the intelligent use of pharmacogenomics, population genetics, and clinical outcomes data. Ultimately, by informed selection of medicines, patients will endure less side effects and achieve treatment benefits for debilitating, progressive diseases. | PanGenX, Inc. | |||||||||||
| private:pangenxinc.-2 | 1458440 | Nov 1st, 2017 12:00AM | PanGenX, Inc. | 222 | 0.00 | Open | Biotechnology | Nov 1st, 2017 04:39AM | Nov 1st, 2017 04:39AM | PanGenX was founded in 2010 with the belief that current treatment outcomes can be improved through effective use of clinical genetic data. We have created a deep collaboration between geneticists and computer scientists. This unique combination has led to the creation of scientifically based, technology driven, decision-making applications to improve the lives of millions of patients suffering worldwide. Our passion, combined with tenacious efforts to challenge status quo drives our team to bring personalized medicine to the forefront of healthcare. Our mission is to advance clinical practice and treatment approaches by integrating genetic variations related to drug response with patient outcomes. We optimize therapeutic care and decision-making by providing pharmaceutical companies, healthcare providers, and payers with tools to conduct analyses and make more informed decisions through the intelligent use of pharmacogenomics, population genetics, and clinical outcomes data. Ultimately, by informed selection of medicines, patients will endure less side effects and achieve treatment benefits for debilitating, progressive diseases. | PanGenX, Inc. |